Next Article in Journal
Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies
Next Article in Special Issue
Protection Conferred by Drinking Water Administration of a Nanoparticle-Based Vaccine against Salmonella Enteritidis in Hens
Previous Article in Journal
An Update on Self-Amplifying mRNA Vaccine Development
Previous Article in Special Issue
Design and Characterization of a DNA Vaccine Based on Spike with Consensus Nucleotide Sequence against Infectious Bronchitis Virus
Article

Immunogenicity and Protective Activity of Pigeon Circovirus Recombinant Capsid Protein Virus-Like Particles (PiCV rCap-VLPs) in Pigeons (Columba livia) Experimentally Infected with PiCV

1
International Degree Program in Animal Vaccine Technology, International College, National Pingtung University of Science and Technology, Pingtung 912, Taiwan
2
Graduate School, University of the Philippines Los Baños, Laguna 4031, Philippines
3
Graduate Institute of Animal Vaccine Technology, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung 912, Taiwan
4
School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
5
Department of Medical Imaging and Radiological Sciences, Kaohsiung Medical University, Kaohsiung 807, Taiwan
6
Institute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung 804, Taiwan
7
Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
8
Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan
9
Center for Cancer Research, Kaohsiung Medical University, Kaohsiung 807, Taiwan
10
Department of Plant Industry, College of Agriculture, National Pingtung University of Science and Technology, Pingtung 912, Taiwan
11
Institute of Biological Sciences, College of Arts and Sciences, University of the Philippines Los Baños, Laguna 4031, Philippines
12
Research Center for Animal Biologics, National Pingtung University of Science and Technology, Pingtung 912, Taiwan
13
School of Dentistry, Kaohsiung Medical University, Kaohsiung 807, Taiwan
*
Author to whom correspondence should be addressed.
Academic Editor: Caterina Lupini
Received: 5 January 2021 / Revised: 24 January 2021 / Accepted: 24 January 2021 / Published: 28 January 2021
(This article belongs to the Special Issue Poultry Vaccines)
Pigeon circovirus (PiCV) is the most recurrent virus diagnosed in pigeons and is among the major causative agents of young pigeon disease syndrome (YPDS). Due to the lack of an established laboratory protocol for PiCV cultivation, development of prophylaxis is hampered. Alternatively, virus-like particles (VLPs), which closely resemble native viruses but lack the viral genetic material, can be generated using a wide range of expression systems and are shown to have strong immunogenicity. Therefore, the use of VLPs provides a promising prospect for vaccine development. In this study, transfected human embryonic kidney (HEK-293) cells, a mammalian expression system, were used to express the PiCV capsid protein (Cap), which is a major component of PiCV and believed to contain antibody epitopes, to obtain self-assembled VLPs. The VLPs were observed to have a spherical morphology with diameters ranging from 12 to 26 nm. Subcutaneous immunization of pigeons with 100 µg PiCV rCap-VLPs supplemented with water-in-oil-in-water (W/O/W) adjuvant induced specific antibodies against PiCV. Observations of the cytokine expression and T-cell proliferation levels in spleen samples showed significantly higher T-cell proliferation and IFN- γ expression in pigeons immunized with VLPs compared to the controls (p < 0.05). Experimentally infected pigeons that were vaccinated with VLPs also showed no detectable viral titer. The results of the current study demonstrated the potential use of PiCV rCap-VLPs as an effective vaccine candidate against PiCV. View Full-Text
Keywords: pigeon circovirus (PiCV); young pigeon disease syndrome (YPDS); virus-like particles (VLPs); immunogenicity; mammalian expression system pigeon circovirus (PiCV); young pigeon disease syndrome (YPDS); virus-like particles (VLPs); immunogenicity; mammalian expression system
Show Figures

Figure 1

MDPI and ACS Style

Huang, H.-Y.; Silva, B.B.I.; Tsai, S.-P.; Tsai, C.-Y.; Tyan, Y.-C.; Lin, T.-C.; Flores, R.J.D.; Chuang, K.-P. Immunogenicity and Protective Activity of Pigeon Circovirus Recombinant Capsid Protein Virus-Like Particles (PiCV rCap-VLPs) in Pigeons (Columba livia) Experimentally Infected with PiCV. Vaccines 2021, 9, 98. https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9020098

AMA Style

Huang H-Y, Silva BBI, Tsai S-P, Tsai C-Y, Tyan Y-C, Lin T-C, Flores RJD, Chuang K-P. Immunogenicity and Protective Activity of Pigeon Circovirus Recombinant Capsid Protein Virus-Like Particles (PiCV rCap-VLPs) in Pigeons (Columba livia) Experimentally Infected with PiCV. Vaccines. 2021; 9(2):98. https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9020098

Chicago/Turabian Style

Huang, Huai-Ying, Benji B.I. Silva, Shen-Pang Tsai, Ching-Yi Tsai, Yu-Chang Tyan, Tzu-Che Lin, Ronilo J.D. Flores, and Kuo-Pin Chuang. 2021. "Immunogenicity and Protective Activity of Pigeon Circovirus Recombinant Capsid Protein Virus-Like Particles (PiCV rCap-VLPs) in Pigeons (Columba livia) Experimentally Infected with PiCV" Vaccines 9, no. 2: 98. https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9020098

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop